/AMGEN%20Inc_%20logo%20on%20website-by%20Jimmy%20Tudeschi%20via%20Shutterstock.jpg)
With a market cap of $158.6 billion, Amgen Inc. (AMGN) is a leading global biotechnology company headquartered in Thousand Oaks, California. Founded in 1980, Amgen focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics for serious illnesses, with a strong emphasis on oncology, nephrology, cardiovascular disease, and inflammation.
The company is expected to release its fiscal Q3 2025 earnings results after the market closes on Tuesday, Nov. 4. Ahead of this event, analysts expect AMGN to report a profit of $5.01 per share, down 10.2% from $5.58 per share in the prior year's quarter. It has consistently surpassed Wall Street's bottom-line estimates in the past four quarters.
For fiscal 2025, analysts predict AMGN to post EPS of $21.10, reflecting a 6.4% increase from $19.84 in fiscal 2024.
AMGN has declined 8.4% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 16.3% gain and the Health Care Select Sector SPDR Fund's (XLV) 6% dip over the same period.
On Oct. 1, shares of Amgen surged 6.4% after the company announced a $650 million investment to expand its U.S. biologics manufacturing facility in Juncos, creating nearly 750 new jobs. CEO Robert Bradway highlighted the move as a commitment to U.S. biomanufacturing and global supply chain strength.
Analysts' consensus rating on AMGN stock is cautiously optimistic, with a "Moderate Buy" rating overall. Out of 33 analysts covering the stock, opinions include 12 "Strong Buys,” two "Moderate Buys," 16 "Holds,” one "Moderate Sell," and two "Strong Sells.” The average analyst price target for AMGN is $315.26, suggesting a potential upside of 6.7% from current levels.
